SCHEMBL3635170

SCHEMBL3635170

CCCC(=O)c1ccc(NCc2cc(-c3ccco3)on2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 6/20 0.48
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
HPGD P15428 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
EPHX2 P34913 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ROCK2 O75116 1/20 0.44
HTT P42858 1/20 0.42
TSHR P16473 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639620 0.83 MAPT (0.49) POLBMAPTALDH1A1NPC1RAB9A
SCHEMBL3637335 0.80 MAPT (0.51) POLBMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3640559 0.80 FRK (0.42) MAPTALDH1A1NPC1RAB9AHPGD
SCHEMBL3640358 0.76 ALDH1A1 (0.53) POLBMAPTALDH1A1NPC1RAB9A
SCHEMBL3639366 0.75 ADORA3 (0.43) POLBMAPTALDH1A1RAB9ALMNA
SCHEMBL3639184 0.73 HPGD (0.52) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL3633399 0.72 TP53 (0.49) MAPTALDH1A1NPC1RAB9AHPGD
SCHEMBL17040354 0.72 NPC1 (0.58) POLBMAPTALDH1A1NPC1RAB9A
SCHEMBL17790250 0.71 EPHX2 (0.53) POLBMAPTALDH1A1NPC1RAB9A
SCHEMBL3637928 0.71 SUCNR1 (0.49) POLBMAPTALDH1A1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 POLB 4225/4885MAPT 572/4885ALDH1A1 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.